Chronic Renal Disease Clinical Trial
— NEIHROfficial title:
Nephrotoxicity of Iopamidol Versus Iodixanol in High-Risk Patients:A Multicentre Randomized Double-Blind Trail of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease
Verified date | August 2013 |
Source | Guangdong General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | China: Ethics Committee |
Study type | Interventional |
The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following the administration of iopamidol-370 (Iopamiro-370) and iodixanol-320 (Visipaque 320) in patients with chronic kidney disease undergoing coronary angiography.
Status | Terminated |
Enrollment | 204 |
Est. completion date | May 2013 |
Est. primary completion date | February 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Provides written Informed Consent and is willing to comply with protocol requirements - Is =18 years of age - Has a documented predose serum creatinine level of =1.5 mg/dL for men and = 1.3 mg/dL for women or predose estimated glomerular ?ltration rate (eGFR) of > 15 and = 60 mL/min/1.73 m2, calculated via the MDRD formula from a SCr obtained within 72 hours of enrollment into the study; - Is referred for cardiac angiography with or without PCI; - If at the discretion of the Investigator is receiving or will be receiving a prophylactic medication for renal function, the medication is one that is permitted by this protocol (N acetylcysteine, 1200 mg twice daily on the day before and on the day of the cardiac angiography procedure); - Undergoes or is scheduled to undergo pre, peri, or post procedure hydration permitted by this protocol, i.e.: - 154 mEq/L sodium bicarbonate solution, administered intravenously at 3 mL/kg/hr for 1 hour before cardiac angiography, followed by an infusion of 1 mL/kg/hr during and out to 6 hours after cardiac angiography, or 0.9% normal saline administered intravenously at 1 mL/kg/hr for 8-12 hours before cardiac angiography, followed by an infusion of 1 mL/kg/hr during and out to 24 hours after cardiac angiography,for the patients with left ventricular ejection fraction <35% or congestive heart failure (class III in accordance with the classification of the New York Heart Association (NYHA), the rate of infusion decreases to half of the above ordinary rate. Exclusion Criteria: - Is a pregnant or lactating female. Exclude the possibility of pregnancy: by laboratory testing on-site at the institution (measurement of serum or urine ßHCG) within 24 hours prior to the start of investigational product administration by history (e.g., tubal ligation or hysterectomy, post menopausal with a minimum 1 year without menses) - Has a history of hypersensitivity to iodine-containing compounds; - Has unstable renal function (i.e., acute worsening of renal function, as determined by the Investigator, that has been observed in the 7 days prior to enrollment) and/or is in acute renal failure; - Has end-stage renal disease (i.e., eGFR <15 mL/min/1.73 m2) - Has severe congestive heart failure (class IV in accordance with the classification of the New York Heart Association (NYHA) ; - Has uncontrolled diabetes, as determined by the Investigator; - Has received an iodinated contrast agent within 7 days prior to the administration of the study agent or is scheduled to receive an iodinated contrast agent within 72 hours after administration of the study agent; intake of nephrotoxic drugs within the previous seven days Prior to, during or post the cardiac angiography, is receiving or will be receiving a prophylactic medication to prevent acute kidney injury that is not permitted by this protocol (e.g., theophylline, fenoldopam, etc.); - Is planned to undergo major surgery (e.g. CABG, valve surgery, etc.) within 48-72 hours after contrast administration; - Is planned to receive an intravenous diuretic or mannitol as prophylaxis to prevent acute renal injury (Note: chronic administration is allowed); - Is hemodynamically unstable within 48 hours pre-contrast administration defined as a systolic blood pressure < 90 mmHg or requires pressor or intra-aortic balloon support |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
China | Guangdong Cardiovascular Institute,Guangdong General Hospital | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Guangdong General Hospital | First Affiliated Hospital, Sun Yat-Sen University, Guangzhou General Hospital of Guangzhou Military Command, Nanfang Hospital of Southern Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | contrast-induced nephropathy | Contrast-Induced Nephropathy was defined as an increase in serum creatinine of more than 0.5 mg/dl or 25% from the baseline within 48-72 h of contrast exposure | 48-72 h | Yes |
Secondary | A relative increase in serum creatinine | A relative increase in serum creatinine was defined as more than 25% increase in serum creatinine within 48-72 h of contrast exposure. | 48-72 h | Yes |
Secondary | A relative increase in estimated glomerular ?ltration rate (eGFR) | A relative increase in eGFR was defined as more than 25% increase in eGFR within 48-72 h of contrast exposure | 48-72 h | Yes |
Secondary | An absolute increase in serum creatinine | An absolute increase in serum creatinine within 48-72 h of contrast exposure | 48-72 h | Yes |
Secondary | Major adverse clinical events | Major adverse clinical events: death, requiring renal replacement therapy, 2nd myocardial infarction,target revascularization,acute heart failure, mechanical ventilation,2nd angina,tachyarrhythmia,hypotension,intra-aortic balloon pump and stroke | 1 month | Yes |
Secondary | Major adverse clinical events | Major adverse clinical events: death, requiring renal replacement therapy, acute myocardial infarction,target revascularization,acute heart failure, mechanical ventilation,2nd angina,tachyarrhythmia,hypotension,intra-aortic balloon pump and stroke | 1 year | Yes |
Secondary | An significant increase in serum creatinine | An significant increase in serum creatinine was defined as an increase in serum creatinine of more than 1.0 mg/dl from the baseline within 48-72 h of contrast exposure | 48-72 h | Yes |
Secondary | Contrast-Induced Acute Kidney Injury | Contrast-Induced Acute Kidney Injury was defined as an increase in serum creatinine concentration of more than 0.3 mg/dL from the baseline value at 48 hours after administration of the contrast exposure or the need for dialysis | 48 h | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT01155128 -
Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00962000 -
Study of How the Dose of Dialysis is Affected by Dialysate Flow Rate
|
N/A | |
Completed |
NCT00560014 -
Nutrient Levels Alter Transplant Outcome
|
N/A | |
Completed |
NCT03274921 -
Biomarkers of Cardiovascular Complications in Chronic Kidney Disease
|
||
Completed |
NCT01964014 -
Once-a-day Immunosuppression(CISECON_a_day)
|
Phase 4 | |
Recruiting |
NCT01728415 -
Effects of High-intensity Interval Training in Patients in Hemodialysis
|
N/A | |
Completed |
NCT01532297 -
Application of Citrate Dialysate in Chronic Haemodialysis
|
N/A | |
Completed |
NCT04100551 -
Relationship Between Chronic Renal Disease and Risk Stratification for Chronic Ulcer on the on the Diabetic Foot
|
||
Recruiting |
NCT04428827 -
Outcome of Patients With Primary Aldosteronism
|
||
Completed |
NCT02299661 -
Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease
|
Phase 1 | |
Recruiting |
NCT02190318 -
Residual Renal Function Preservation in Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT04157647 -
Hemadsorption During and After Cardiopulmonary Bypass to Modulate the Inflammatory Response
|
N/A | |
Completed |
NCT04897672 -
2D-speckle Tracking in Pediatric Renal Chronic Disease
|
||
Terminated |
NCT02375711 -
Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient
|
N/A | |
Not yet recruiting |
NCT04940819 -
A Mobile Application Based Dietary Self Management Intervention in Chinese Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT01817322 -
Kidney Graft Function Under the Immunosuppression Strategies
|
Phase 4 | |
Completed |
NCT05383261 -
The Impact of the Social Factors and Rehabilitation Program to Address the Implications on Kidney Failure in Hail
|
||
Not yet recruiting |
NCT06439862 -
Study of the Quality of Life in School Aged-children With Posterior Urethral Valves
|
||
Completed |
NCT02834026 -
Impact of the Cycle Ergometer in Muscle Strength and Pulmonary Function in Patients in Hemodialysis
|
N/A | |
Completed |
NCT02072837 -
Dyslipidemia-related Risk Factors in Dialysis
|
N/A |